High Court To Tackle Novo Nordisk's Generic Drug Fight
The U.S. Supreme Court on Monday will examine a Federal Circuit ruling limiting the power of generics makers to challenge patent information filed with the U.S. Food and Drug Administration, a...To view the full article, register now.
Already a subscriber? Click here to view full article